NEUROPHET
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Seed | ||
N/A | N/A | Seed | |
N/A | $5.1m | Series A | |
KRW3.0b | Series A | ||
KRW28.5b | Series B | ||
* | KRW20.0b Valuation: KRW142.5b | Series C | |
Total Funding | $48.3m |
Related Content
Recent News about NEUROPHET
EditNeurophet is a medical software company specializing in advanced neuroscience technologies to overcome medical limitations. The company focuses on developing software for the computational analysis of transcranial electrical stimulation (tES), including transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Their flagship product, Neurophet tES LAB, offers easy and powerful FEM (Finite Element Method) simulation of stimulation effects using personalized brain models. This software significantly reduces research time, making it possible to conduct complex brain engineering studies in minutes. Neurophet serves researchers and medical professionals in the brain stimulation field, providing them with cutting-edge tools to accelerate their studies. The company operates in the medical software market and generates revenue through software licensing. Neurophet has been recognized for its user-friendly interface design, winning the Red Dot Award in 2018, and has been selected into the Philips Healthworks global startup program.
Keywords: neuroscience, brain stimulation, tDCS, tACS, FEM simulation, medical software, personalized brain models, research acceleration, software licensing, user-friendly design.